-
Introduction to the whole process of CAR-T cell clinical treatment: Taking lymphoma as an exampleAs of April 16, 2021, there are 2,073 cell therapy drugs under development worldwide, of which CAR-T therapies account for 1,164, dominating the market with an ...05-30 -
In-depth assessment of the development process of CRS - providing the best intervention window and rChimeric antigen receptor-modified T cell (CAR-T) therapy is currently a powerful approach to combat hematological malignancies, but cytokine release syndrome (...05-30 -
Anti-cancer effects of NK from different sources such as peripheral blood and umbilical cord bloodIntroduction In the minds of most people today, cancer is still an incurable disease. Both the illness experience and the traditional treatment process are v...05-16 -
Off-the-shelf CAR-T cell therapy against host immune rejectionIn recent years, CAR-T cell therapy has become a promising cancer treatment. However, due to the high cost of CAR-T therapy and the differences in patients'...05-15 -
Comparison of CAR-NK cells derived from adult peripheral blood and umbilical cord bloodAmong hematological cancers, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are the most common leukemias in children and the elderly...05-15 -
Safety, efficacy, and determinants of allogeneic CAR-NK cell therapy for tumors: a phase 1/2 trialCAR-T cell therapy marks the advent of the era of cell therapy. However, CAR-T cells have their limitations, including treatment costs, manufacturing time, and ...05-15
